Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials

Meredith M. Regan, Olivia Pagani, Gini F. Fleming, Barbara A. Walley, Karen N. Price, Manuela Rabaglio, Rudolf Maibach, Barbara Ruepp, Alan S. Coates, Aron Goldhirsch, Marco Colleoni, Richard D. Gelber, Prudence A. Francis

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: In 2003 the International Breast Cancer Study Group (IBCSG) initiated the TEXT and SOFT randomized phase III trials to answer two questions concerning adjuvant treatment for premenopausal women with endocrine-responsive early breast cancer: 1-What is the role of aromatase inhibitors (AI) for women treated with ovarian function suppression (OFS)? 2-What is the role of OFS for women who remain premenopausal and are treated with tamoxifen? Methods: TEXT randomized patients to receive exemestane or tamoxifen with OFS. SOFT randomized patients to receive exemestane with OFS, tamoxifen with OFS, or tamoxifen alone. Treatment was for 5 years from randomization. Results: TEXT and SOFT successfully met their enrollment goals in 2011. The 5738 enrolled women had lower-risk disease and lower observed disease-free survival (DFS) event rates than anticipated. Consequently, 7 and 13 additional years of follow-up for TEXT and SOFT, respectively, were required to reach the targeted DFS events (median follow-up about 10.5 and 15 years). To provide timely answers, protocol amendments in 2011 specified analyses based on chronological time and median follow-up. To assess the AI question, exemestane+OFS versus tamoxifen+OFS, a combined analysis of TEXT and SOFT became the primary analysis (. n=4717). The OFS question became the primary analysis from SOFT, assessing the unique comparison of tamoxifen+OFS versus tamoxifen alone (. n=2045). The first reports are anticipated in mid- and late-2014. Conclusions: We present the original designs of TEXT and SOFT and adaptations to ensure timely answers to two questions concerning optimal adjuvant endocrine treatment for premenopausal women with endocrine-responsive breast cancer.Trial RegistrationTEXT: Clinicaltrials.gov NCT00066703SOFT: Clinicaltrials.gov NCT00066690.

Original languageEnglish
Pages (from-to)1094-1100
Number of pages7
JournalBreast
Volume22
Issue number6
DOIs
Publication statusPublished - Dec 2013

Keywords

  • Adjuvant therapy
  • Early breast cancer
  • Endocrine-responsive
  • Premenopausal
  • Trial design

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials'. Together they form a unique fingerprint.

Cite this